Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT03973723 Completed - Clinical trials for Nasopharyngeal Carcinoma

Plasma EBV DNA Monitoring in Post-treatment NPC Patients

Start date: August 1, 2011
Phase:
Study type: Observational

Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated. The investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in NPC patients after curative treatment.

NCT ID: NCT03942380 Recruiting - Clinical trials for Head and Neck Cancer

Cell-free Tumor DNA in Head and Neck Cancer Patients

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

This study investigates if head and neck squamous cell carcinoma can be tracked with cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion of cancer, and if it can be used in detecting recurrence in patients already diagnosed and treated for head and neck squamous cell carcinoma.

NCT ID: NCT03932266 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Start date: June 2019
Phase: Phase 2
Study type: Interventional

Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.

NCT ID: NCT03930498 Recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk recurrent nasopharyngeal carcinoma.

NCT ID: NCT03925896 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients

Start date: August 7, 2019
Phase: Phase 1
Study type: Interventional

In this study, a single-arm, open-labeled clinical trial will be performed to determine the safety and efficacy of EBV TCR-T cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma with positive EBV infection in the Chinese population.

NCT ID: NCT03925090 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Start date: December 8, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized Phase II trial to study the effectiveness and toxicity of neoadjuvant and adjuvant PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy plus placebo in treating patients with high risk locoregionally advanced nasopharyngeal carcinoma.

NCT ID: NCT03924986 Active, not recruiting - Clinical trials for Recurrent or Metastatic Nasopharyngeal Cancer

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Start date: April 18, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer.

NCT ID: NCT03923842 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours

Dern
Start date: June 30, 2019
Phase: Phase 2
Study type: Interventional

The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first line NPC recurrent/metastatic patients

NCT ID: NCT03919552 Recruiting - NPC Clinical Trials

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: January 31, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare cisplatin-based with carboplatin-based chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of carboplatin-based chemoradiotherapy in NPC patients.

NCT ID: NCT03915132 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and toxicity of Nimotuzumab combined with VMAT in the treatment of elderly patients with nasopharyngeal carcinoma (> 70 years old), and to provide high-level clinical evidence for the optimal treatment of elderly patients with nasopharyngeal carcinoma.